CME and CFTC Clash Over On-Chain Perpetual Futures

The Commodity Futures Trading Commission's recent decision to allow blockchain-based perpetual futures products has ignited a heated battle with the CME Group, the largest derivatives exchange operator in the US. The CME has filed a lawsuit against the CFTC, challenging its decision to permit the listing of crypto perpetual futures, also known as perps, on platforms such as Kalshi and Coinbase. The CME argues that these products are harmful to its traditional futures contracts and that the CFTC has failed to consider the implications of its decision. The regulator, however, maintains that it has the authority to approve these products and that they are essential for the growth of the crypto market. The dispute has significant implications for the US approach to the rapidly evolving crypto derivatives market, with non-US perps volume reportedly reaching $60 trillion in volume last year. The CME's lawsuit claims that the CFTC is mislabeling perps as futures, which require an end date, and that the products are designed for traders to take a financial position on an asset's future without any deadlines. The CFTC's decision to approve perps has been met with frustration from some industry players, who argue that the regulator is not considering the potential risks and consequences of these products. The CME's chairman, Terry Duffy, has been vocal in his opposition to perps, stating that they are not suitable for institutional clients and that the CME has the technical capabilities to launch perps but has not seen demand from its customers. The dispute highlights the ongoing tension between traditional financial institutions and the growing crypto market, with some arguing that the CME is trying to stifle innovation and competition. The outcome of the lawsuit is likely to have significant implications for the future of crypto derivatives in the US, with some predicting that it could lead to increased regulatory clarity and others warning that it could stifle innovation and growth. As the CME prepares its case, the CFTC remains committed to its decision to approve perps, with Chairman Mike Selig stating that the regulator is committed to allowing challengers to traditional incumbents and promoting competition in the market.